News & Updates
Filter by Specialty:
One BPG dose may be enough to treat syphilis, regardless of HIV status
Three doses of benzathine penicillin G (BPG) are not necessarily better than a single dose in the treatment of early syphilis in individuals with or without HIV infection, as shown in a study.
One BPG dose may be enough to treat syphilis, regardless of HIV status
26 Oct 2023
Pooled EAGLE subgroup analyses boost gepotidacin potential for uUTI in females
In a pooled analyses of data from the EAGLE*-2 and EAGLE-3 studies, the investigational, first-in-class, oral, triazaacenaphthylene bactericidal antibiotic gepotidacin showed consistent therapeutic efficacy across key patient subgroups and had an acceptable safety profile in female adults and adolescents with uncomplicated urinary tract infections (uUTI) compared with nitrofurantoin.
Pooled EAGLE subgroup analyses boost gepotidacin potential for uUTI in females
25 Oct 2023
How safe is long-term bimekizumab in plaque psoriasis patients?
Treatment with bimekizumab (BKZ) for over 3 years does not result in the occurrence of new adverse events (AEs), demonstrating its positive safety profile in patients with moderate-to-severe plaque psoriasis, as shown by a pooled analysis of five phase III/IIIb trials presented at EADV 2023.
How safe is long-term bimekizumab in plaque psoriasis patients?
24 Oct 2023
COVID shots hold up against Omicron XBB for youngest kids in SG
The monovalent mRNA vaccine helped stave off severe COVID-19 outcomes in children aged 1 to 4 years during the Omicron wave, as shown in a study from Singapore.
